Our mission To create a better, more engaging healthcare experience. We are a leading provider of comprehensive solutions that transform the healthcare experience by engaging patients in their care and enabling healthcare provider organizations to optimize operational efficiency, improve profitability and enhance clinical care. As evidenced in industry survey reports from KLAS, we have been recognized as a leader based on our integration capabilities with healthcare provider organizations, the broad adoption of our patient intake functionalities and by overall client satisfaction. Through the SaaS-based Phreesia Platform (the “Phreesia Platform” or “our Platform”), we offer healthcare provider organizations (our “provider clients”) a robust suite of solutions to manage the patient intake process and an integrated payments solution for secure processing of patient payments. Our Platform also provides life sciences companies with an engagement channel for targeted and direct communication with patients. In fiscal 2019, we facilitated more than 54 million patient visits for approximately 50,000 individual providers, including physicians, physician assistants and nurse practitioners, in nearly 1,600 healthcare provider organizations across all 50 states. We define a patient visit as an individual, in-person visit to a healthcare provider, which may include multiple visits by the same patient. Additionally, our Platform processed more than $1.4 billion in patient payments in fiscal 2019.
Use of proceeds:We estimate that the net proceeds to us from the sale of the shares of our common stock in this offering will be approximately $111.2 million, based upon an assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.We will not receive any proceeds from the sale of common stock by the selling stockholders if the underwriters exercise their option to purchase additional shares.Each $1.00 increase (decrease) in the assumed initial public offering price of $16.00 per share, the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by approximately $7.6 million and $(7.3) million, respectively, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.An increase (decrease) of 1,000,000 shares in the number of shares offered by us would increase (decrease) the net proceeds to us from this offering by approximately $14.9 million, assuming that the assumed initial public offering price remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us.We do not expect that a change in the initial public offering price or the number of shares by these amounts would have a material effect on our uses of the proceeds from this offering, although it may accelerate the time at which we will need to seek additional capital.The principal purposes of this offering are to increase our capitalization and financial flexibility, create a public market for our common stock and enable access to the public equity markets for us and our stockholders.We intend to use approximately $18.1 million to pay a cash dividend to the holders of 22,871,507 shares of our Senior Convertible preferred stock, which is payable to such holders upon the conversion of all such shares into an aggregate of 10,408,818 shares of our common stock upon the closing of this offering.This cash dividend is calculated based on an assumed closing date for this offering of July 22, 2019, and an assumed initial public offering price of $16.00 per share, which is the midpoint of the price range set forth on the cover page of this prospectus.If this offering closes one day prior to the assumed closing date of July 22, 2019, such cash dividends decrease by an aggregate amount of approximately $17,000; if this offering closes one day following the assumed closing date of July 22, 2019, such cash dividends increase by an aggregate amount of approximately $17,000.In addition, a $1.00 increase in the assumed initial public offering price of $16.00 would decrease the cash dividend payable to holders of our Senior Convertible preferred stock by an aggregate of $0.4 million; We also currently intend to use $17.7 million of the net proceeds from this offering to repay all of our revolving line of credit with Silicon Valley Bank, which has an outstanding balance of $17,675,556 as of July 8, 2019 ($15,175,556 as of April 30, 2019).Our credit facility with Silicon Valley Bank consists of an asset based line of credit with a maturity date of February 28, 2024, which accrues interest at the greater of prime rate minus 0.50% and 5.00%.The term loan also has a maturity date of February 28, 2024 in which principal payments under the term loan are due in 36 equal monthly installments beginning in March, 2021, accruing an annum interest at prime rate plus 1.50%.We have used our credit facility to pay the outstanding principal amount under a loan and security agreement with another lender.We intend to use the remaining net proceeds we receive from this offering for general corporate purposes, including working capital, operating expenses and capital expenditures.Additionally, we may use a portion of the net proceeds we receive from this offering to acquire or invest in businesses, products, services or technologies.However, we do not have agreements or commitments for any material acquisitions or investments at this time.We cannot specify with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering.Accordingly, we will have broad discretion in using these proceeds, and you will not have the opportunity to influence decisions on the use of these proceeds.Pending their uses, we plan to invest the net proceeds of this offering in interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.
Competition:The market for our products and services is fragmented, competitive and characterized by rapidly evolving technology standards, client needs and the frequent introduction of new products and services.Our competitors range from smaller niche companies to large, well-financed and technologically-sophisticated entities.As costs fall and technology improves, increased market saturation may change the competitive landscape in favor of competitors with greater scale than we currently possess.We compete on the basis of several factors, including breadth, depth and quality of product and service offerings, ability to deliver clinical, financial and operational performance improvement through the use of products and services, quality and reliability of services, ease of use and convenience, brand recognition and the ability to integrate our Platform solutions with various PM and EHR systems and other technology.Some of our competitors have greater name recognition, longer operating histories and significantly greater resources than we do.As a result, our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or client requirements.In addition, current and potential competitors have established, and may in the future establish, cooperative relationships with vendors of complementary products, technologies or services to increase the availability of their products to the marketplace.Accordingly, new competitors or alliances may emerge that have greater market share, larger client bases, more widely adopted proprietary technologies, greater marketing expertise, greater financial resources and larger sales forces than we have, which could put us at a competitive disadvantage.Further, in light of these advantages, even if our services are more effective than the product or service offerings of our competitors, current or potential clients might accept competitive products and services in lieu of purchasing our services.In addition to new niche vendors, who offer stand-alone products and services, we also face competition from PM and EHR providers, including those with which we have integration partnerships.PM or EHR providers may have existing systems in place at clients in our target market.These PM and EHR providers may now, or in the future, offer or promise products or services similar to ours, and which offer ease of integration with existing systems and which leverage existing client and vendor relationships.We also compete on the basis of price.We may be subject to pricing pressures as a result of, among other things, competition within the industry, consolidation of healthcare industry participants, practices of managed care organizations, government action and financial stress experienced by our clients.If our pricing experiences significant downward pressure, our business will be less profitable and our results of operations will be adversely affected.We cannot be certain that we will be able to retain our current clients or expand our client base in this competitive environment.If we do not retain current clients or expand our client base, or if we have to renegotiate existing contracts, our business, financial condition and results of operations will be harmed.Moreover, we expect that competition will continue to increase as a result of consolidation in both the healthcare information technology and healthcare industries.If one or more of our competitors or potential competitors were to merge or partner with another of our competitors, the change in the competitive landscape could also adversely affect our ability to compete effectively and could harm our business, financial condition and results of operations.